24,189 results match your criteria British Journal of Cancer[Journal]


CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer.

Br J Cancer 2020 Jul 1. Epub 2020 Jul 1.

Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.

Background: Toward identifying new strategies to target gastric cancer stem-like cells (CSCs), we evaluated the function of the tumour suppressor CDK5 regulatory subunit-associated protein 3 (CDK5RAP3) in gastric CSC maintenance.

Methods: We examined the expression of CDK5RAP3 and CD44 in gastric cancer patients. The function and mechanisms of CDK5RAP3 were checked in human and mouse gastric cancer cell lines and in mouse xenograft. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0963-yDOI Listing

EGFR/Ras-induced CCL20 production modulates the tumour microenvironment.

Br J Cancer 2020 Jun 30. Epub 2020 Jun 30.

Department of Dermatology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.

Background: The activation of the EGFR/Ras-signalling pathway in tumour cells induces a distinct chemokine repertoire, which in turn modulates the tumour microenvironment.

Methods: The effects of EGFR/Ras on the expression and translation of CCL20 were analysed in a large set of epithelial cancer cell lines and tumour tissues by RT-qPCR and ELISA in vitro. CCL20 production was verified by immunohistochemistry in different tumour tissues and correlated with clinical data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0943-2DOI Listing

Tumour budding and its clinical implications in gastrointestinal cancers.

Br J Cancer 2020 Jun 30. Epub 2020 Jun 30.

Institute of Pathology, University of Bern, Bern, Switzerland.

Tumour budding in colorectal cancer has become an important prognostic factor. Represented by single cells or small tumour cell clusters at the invasion front of the tumour mass, these tumour buds seem to reflect cells in a 'hybrid' state of epithelial-mesenchymal transition, and evidence indicates that the presence of these entities is associated with lymph node metastasis, local recurrence and distant metastatic disease. The International Tumour Budding Consensus Conference (ITBCC) has highlighted a scoring system for the reporting of tumour budding in colorectal cancer, as well as different clinical scenarios that could affect patient management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0954-zDOI Listing

WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness.

Br J Cancer 2020 Jun 30. Epub 2020 Jun 30.

Department of Pancreatic surgery, Huashan Hospital, Fudan University, Shanghai, 200040, P. R. China.

Background: The molecular signature underlying pancreatic ductal adenocarcinoma (PDAC) progression may include key proteins affecting the malignant phenotypes. Here, we aimed to identify the proteins implicated in PDAC with different tumour-node-metastasis (TNM) stages.

Methods: Eight-plex isobaric tags coupled with two-dimensional liquid chromatography-tandem mass spectrometry were used to analyse the proteome of PDAC tissues with different TNM stages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0929-0DOI Listing

Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature.

Br J Cancer 2020 Jun 29. Epub 2020 Jun 29.

Department of Radiation Oncology, Curie Institute, Paris, France.

Palbociclib in combination with endocrine therapy increases progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer (BC). In this study, we retrospectively evaluated safety in the first patient treated with concurrent use of palbociclib and radiation therapy (RT) in the Curie Institute. Between April 2017 and August 2019, 30 women with metastatic BC received locoregional and/or symptomatic irradiation at a metastatic site concurrently with palbociclib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0957-9DOI Listing

New tools to prevent cancer growth and spread: a 'Clever' approach.

Br J Cancer 2020 Jun 29. Epub 2020 Jun 29.

MediCity Research Laboratory and Institute of Biomedicine, University of Turku, Turku, Finland.

Clever-1 (also known as Stabilin-1 and FEEL-1) is a scavenger receptor expressed on lymphatic endothelial cells, sinusoidal endothelial cells and immunosuppressive monocytes and macrophages. Its role in cancer growth and spread first became evident in Stab1 knockout mice, which have smaller primary tumours and metastases. Subsequent studies in mice and humans have shown that immunotherapeutic blockade of Clever-1 can activate T-cell responses, and that this response is mainly mediated by a phenotypic change in macrophages and monocytes from immunosuppressive to pro-inflammatory following Clever-1 inhibition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0953-0DOI Listing

An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.

Br J Cancer 2020 Jun 29. Epub 2020 Jun 29.

Department of Microbiology and Immunology, College of Medicine, The Catholic University of Korea, Seoul, 06591, South Korea.

Background: Therapeutic cancer vaccines are an attractive approach for treating malignant tumours, and successful tumour eradication depends primarily on controlling tumour immunosuppression status as well as heterogeneity of tumour cells driven by epigenetic alterations.

Methods: Peptide-loaded dendritic cell (DC) prime and non-infectious peptide booster heterologous immunisations were assessed for the immunogenicity of polo-like kinase-1 (PLK1)-derived peptides. Heterologous vaccination regimen targeting multiple shared tumour antigens simultaneously with PD-L1 blockade was assessed against murine myeloid leukaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0955-yDOI Listing

Seropositivity for Helicobacter pylori and hepatobiliary cancers in the PLCO study.

Br J Cancer 2020 Jun 29. Epub 2020 Jun 29.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Helicobacter has been suggested to play a possible role in hepatitis, gallstones, and hepatobiliary tumours. We assessed whether seropositivity to 15 H. pylori proteins was associated with subsequent incidence of 74 biliary tract and 105 liver cancer cases vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0961-0DOI Listing

Syntenin-1 promotes colorectal cancer stem cell expansion and chemoresistance by regulating prostaglandin E2 receptor.

Br J Cancer 2020 Jun 29. Epub 2020 Jun 29.

Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Background: The protein syntenin-1 is expressed by a variety of cell types, and is upregulated in various malignancies, including melanoma, breast cancer and glioma. Although the mechanism by which elevated syntenin-1 expression contributes to cancer has been described, the exact pathway has not been elucidated.

Methods: To investigate the involvement of syntenin-1 in colorectal cancer (CRC), we performed immunohistochemical analysis of 139 CRC surgical specimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0965-9DOI Listing

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.

Br J Cancer 2020 Jun 29. Epub 2020 Jun 29.

Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, University of Paris, Paris, France.

Background: Pretherapeutic screening for dihydropyrimidine dehydrogenase (DPD) deficiency is recommended or required prior to the administration of fluoropyrimidine-based chemotherapy. However, the best strategy to identify DPD-deficient patients remains elusive.

Methods: Among a nationwide cohort of 5886 phenotyped patients with cancer who were screened for DPD deficiency over a 3 years period, we assessed the characteristics of both DPD phenotypes and DPYD genotypes in a subgroup of 3680 patients who had completed the two tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0962-zDOI Listing

COVID-19 and cancer research.

Authors:
Adrian L Harris

Br J Cancer 2020 Jun 26. Epub 2020 Jun 26.

Editor-in-Chief, BJC Editorial Office, British Journal of Cancer, Cancer Research UK, 2 Redman Place London, London, E20 1JQ, UK.

The COVID-19 pandemic has had a devastating effect on human lives and society. The accompanying editorial summarises some of the major effects on cancer patients and impacts on cancer research. These may be mitigated by appropriate responses from governments, research funders, charities, universities, industry and the public. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0960-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317074PMC

Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.

Br J Cancer 2020 Jun 26. Epub 2020 Jun 26.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

With the recent approval of the combinations of axitinib with the immune checkpoint inhibitor (ICI) pembrolizumab or avelumab for first-line treatment of advanced renal cell carcinoma, guidance on how to distinguish between immune-related adverse events (AEs) caused by ICI versus axitinib-related AEs is necessary to optimise therapy with axitinib-ICI combinations. The recommendations here are based on (1) systematic review of published evidence, (2) discussion among experts in the field and (3) a survey to obtain expert consensus on specific measures for therapy management with the combinations axitinib/avelumab and axitinib/pembrolizumab. The experts identified areas of AEs requiring unique management during treatment with axitinib-ICI combinations that were not covered by current recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0949-9DOI Listing

How promising is phototherapy for cancer?

Br J Cancer 2020 Jun 26. Epub 2020 Jun 26.

Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.

Oncological phototherapy, including current photodynamic therapy (PDT), developmental photoactivated chemotherapy (PACT) and photothermal therapy (PTT), shows promising photo-efficacy for superficial and internal tumours. The dual application of light and photochemotherapeutic agents allows accurate cancer targeting, low invasiveness and novel mechanisms of action. Current advances in new light sources and photoactive agents are encouraging for future development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0926-3DOI Listing

Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.

Br J Cancer 2020 Jun 25. Epub 2020 Jun 25.

Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK.

Background: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefore significant interest in developing novel therapeutic agents that target ERG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0951-2DOI Listing

Radiation-induced bystander and abscopal effects: important lessons from preclinical models.

Br J Cancer 2020 Jun 25. Epub 2020 Jun 25.

Département de Radiothérapie, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.

Radiotherapy is a pivotal component in the curative treatment of patients with localised cancer and isolated metastasis, as well as being used as a palliative strategy for patients with disseminated disease. The clinical efficacy of radiotherapy has traditionally been attributed to the local effects of ionising radiation, which induces cell death by directly and indirectly inducing DNA damage, but substantial work has uncovered an unexpected and dual relationship between tumour irradiation and the host immune system. In clinical practice, it is, therefore, tempting to tailor immunotherapies with radiotherapy in order to synergise innate and adaptive immunity against cancer cells, as well as to bypass immune tolerance and exhaustion, with the aim of facilitating tumour regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0942-3DOI Listing

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.

Br J Cancer 2020 Jun 22. Epub 2020 Jun 22.

Mayo Clinic, Rochester, MN, USA.

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0948-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307309PMC

Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response.

Br J Cancer 2020 Jun 22. Epub 2020 Jun 22.

Department of Internal Medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

An amendment to this paper has been published and can be accessed via a link at the top of the paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0944-1DOI Listing

YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.

Br J Cancer 2020 Jun 23. Epub 2020 Jun 23.

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.

Background: Trastuzumab-emtansine (T-DM1), one of the most potent HER2-targeted drugs, shows impressive efficacy in patients with HER2-positive breast cancers. However, resistance inevitably occurs and becomes a critical clinical problem.

Methods: We modelled the development of acquired resistance by exposing HER2-positive cells to escalating concentrations of T-DM1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0952-1DOI Listing

Gremlin-1 augments the oestrogen-related receptor α signalling through EGFR activation: implications for the progression of breast cancer.

Br J Cancer 2020 Jun 23. Epub 2020 Jun 23.

Tumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National University, Seoul, 08826, South Korea.

Background: Gremlin-1 (GREM1), one of the bone morphogenetic protein antagonists, is involved in organogenesis, tissue differentiation and kidney development. However, the role of GREM1 in cancer progression and its underlying mechanisms remain poorly understood.

Methods: The role of GREM1 in breast cancer progression was assessed by measuring cell viability, colony formation, 3D tumour spheroid formation/invasion and xenograft tumour formation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0945-0DOI Listing

Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma.

Br J Cancer 2020 Jun 22. Epub 2020 Jun 22.

INSERM Unit 1218, Université de Bordeaux, Bordeaux, France.

Background: Cytochrome P450 1B1 (CYP1B1) is mostly expressed in tumours and displays unusual properties. Its two polymorphic forms were differently associated with anticancer drug sensitivity. We decipher here the role of this polymorphism in anticancer drug efficacy in vitro, in vivo and in the clinical setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0932-5DOI Listing

Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations.

Br J Cancer 2020 Jun 22. Epub 2020 Jun 22.

Department of Clinical Research, Faculty of Medicine, University of Basel, Basel, Switzerland.

Background: The clinical utility of machine-learning (ML) algorithms for breast cancer risk prediction and screening practices is unknown. We compared classification of lifetime breast cancer risk based on ML and the BOADICEA model. We explored the differences in risk classification and their clinical impact on screening practices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0937-0DOI Listing

Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.

Br J Cancer 2020 Jun 22. Epub 2020 Jun 22.

Project for Development of Liquid Biopsy Diagnosis, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

Background: The "watch-and-wait" approach is a common treatment option amongst patients with locally advanced rectal cancer (LARC). However, the diagnostic sensitivity of clinical modalities, such as colonoscopy and magnetic resonance imaging to determine pathological response, is not high. We analysed the clinical utility of circulating tumour DNA (ctDNA) of patients with LARC to predict response to preoperative therapy and postoperative recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0941-4DOI Listing

Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data.

Br J Cancer 2020 Jun 19. Epub 2020 Jun 19.

Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Background: We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology.

Methods: Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0938-zDOI Listing
June 2020
4.836 Impact Factor

Correction: Association between the National Cancer Screening Programme (NSCP) for gastric cancer and oesophageal cancer mortality.

Br J Cancer 2020 Jun 17. Epub 2020 Jun 17.

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

An amendment to this paper has been published and can be accessed via a link at the top of the paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0946-zDOI Listing

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

Authors:
Filipe Correia Martins Dominique-Laurent Couturier Anna Paterson Anthony N Karnezis Christine Chow Tayyebeh M Nazeran Adekunle Odunsi Aleksandra Gentry-Maharaj Aleksandra Vrvilo Alexander Hein Aline Talhouk Ana Osorio Andreas D Hartkopf Angela Brooks-Wilson Anna DeFazio Anna Fischer Arndt Hartmann Brenda Y Hernandez Bryan M McCauley Chloe Karpinskyj Christiani B de Sousa Claus Høgdall Daniel G Tiezzi Esther Herpel Florin Andrei Taran Francesmary Modugno Gary Keeney Gregg Nelson Helen Steed Honglin Song Hugh Luk Javier Benitez Jennifer Alsop Jennifer M Koziak Jenny Lester Joseph H Rothstein Jurandyr M de Andrade Lene Lundvall Luis Paz-Ares Luis Robles-Díaz Lynne R Wilkens Maria J Garcia Maria P Intermaggio Marie-Lyne Alcaraz Mary A Brett Matthias W Beckmann Mercedes Jimenez-Linan Michael Anglesio Michael E Carney Michael Schneider Nadia Traficante Nadja Pejovic Naveena Singh Nhu Le Peter Sinn Prafull Ghatage Ramona Erber Robert Edwards Robert Vierkant Roberta B Ness Samuel Leung Sandra Orsulic Sara Y Brucker Scott H Kaufmann Sian Fereday Simon Gayther Stacey J Winham Stefan Kommoss Tanja Pejovic Teri A Longacre Valerie McGuire Valerie Rhenius Weiva Sieh Yurii B Shvetsov Alice S Whittemore Annette Staebler Beth Y Karlan Cristina Rodriguez-Antona David D Bowtell Ellen L Goode Estrid Høgdall Francisco J Candido Dos Reis Jacek Gronwald Jenny Chang-Claude Kirsten B Moysich Linda E Kelemen Linda S Cook Marc T Goodman Peter A Fasching Robin Crawford Suha Deen Usha Menon David G Huntsman Martin Köbel Susan J Ramus Paul D P Pharoah James D Brenton

Br J Cancer 2020 Jun 18. Epub 2020 Jun 18.

Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, England.

Background: PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker in epithelial ovarian cancer in a large population-based study.

Methods: Tumours from 5400 patients from a multicentre observational, prospective cohort study of the Ovarian Tumour Tissue Analysis Consortium were used to evaluate associations between immunohistochemical PTEN patterns and overall survival time, age, stage, grade, residual tumour, CD8+ tumour-infiltrating lymphocytes (TIL) counts, expression of oestrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR) by means of Cox proportional hazard models and generalised Cochran-Mantel-Haenszel tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0900-0DOI Listing

Concurrent chemo-radiotherapy with proton therapy: reduced toxicity with comparable oncological outcomes vs photon chemo-radiotherapy.

Br J Cancer 2020 Jun 18. Epub 2020 Jun 18.

Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Concurrent chemo-radiotherapy is a commonly employed curative treatment approach for locally advanced cancers but is associated with considerable morbidity. Chemo-radiotherapy using proton therapy may be able to reduce side effects of treatment and improve efficacy, but this remains an area of controversy and data are relatively limited. We comment on recently published studies and discuss future directions for proton therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0919-2DOI Listing

Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?

Br J Cancer 2020 Jun 16. Epub 2020 Jun 16.

Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0930-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296191PMC

A dynamic web-based decision aid to improve informed choice in organised breast cancer screening. A pragmatic randomised trial in Italy.

Br J Cancer 2020 Jun 17. Epub 2020 Jun 17.

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.

Background: Improving the quality of information and communication is a priority in organised breast cancer screening and an ethical duty. Programmes must offer the information each woman is looking for, promoting informed decision-making. This study aimed to develop and evaluate a web-based dynamic decision aid (DA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0935-2DOI Listing

MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer.

Br J Cancer 2020 Jun 17. Epub 2020 Jun 17.

Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.

Background: Epithelial-mesenchymal transition (EMT) is the most common cause of death in colorectal cancer (CRC). In this study, we investigated the functional roles of miRNA-17-5p in EMT of CRC cells.

Methods: In order to determine if miRNA-17-5p regulated EMT, the precursors and inhibitors of miR-17-5p were transduced into four CRC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0940-5DOI Listing

Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models.

Br J Cancer 2020 Jun 17. Epub 2020 Jun 17.

INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.

Background: Subcutaneous mouse tumour models are widely used for the screening of novel antitumour treatments, although these models are poor surrogate models of human cancers.

Methods: We compared the antitumour efficacy of the combination of ionising radiation (IR) with two DNA damage response inhibitors, the PARP inhibitor olaparib and the ATR inhibitor AZD6738 (ceralasertib), in subcutaneous versus orthotopic cancer models.

Results: Olaparib delayed the growth of irradiated Lewis lung carcinoma (LL2) subcutaneous tumours, in agreement with previous reports in human cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0931-6DOI Listing

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.

Br J Cancer 2020 Jun 16. Epub 2020 Jun 16.

Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.

Background: The epidermal growth factor receptor (EGFR) is overexpressed by 80-90% of squamous cell carcinoma of head and neck (HNSCC). In addition to inhibiting EGFR signal transduction, cetuximab, a monoclonal antibody targeting EGFR can also bind to fragment crystallisable domain of immunoglobulins G1 present on natural killer (NK), causing antibody-dependent cellular cytotoxicity (ADCC). However, presence of cetuximab resistance limits effective clinical management of HNSCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0934-3DOI Listing

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC.

Br J Cancer 2020 Jun 16. Epub 2020 Jun 16.

Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, Inserm U1068, CNRS UMR 7258, Institut Paoli Calmettes, 13009, Marseille, France.

This project aims to generate dense longitudinal data in lung cancer patients undergoing anti-PD1/PDL1 therapy. Mathematical modelling with mechanistic learning algorithms will help decipher the mechanisms underlying the response or resistance to immunotherapy. A better understanding of these mechanisms should help identifying actionable items to increase the efficacy of immune-checkpoint inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0918-3DOI Listing
June 2020
4.836 Impact Factor

Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies.

Br J Cancer 2020 Jun 16. Epub 2020 Jun 16.

Dana-Farber Cancer Institute, Boston, MA, USA.

Background: Despite several plausible biological mechanisms linking proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) with colorectal tumorigenesis, their association with risk of colorectal cancer (CRC) has not been adequately assessed in prospective epidemiological studies.

Methods: We evaluated the association of acid-suppressive medication use with CRC risk among 175,871 (PPI) and 208,831 (H2RA) participants from three large prospective cohort studies. Medication use was assessed at baseline and updated biennially. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0939-yDOI Listing

The myth of pulmonary metastasectomy.

Br J Cancer 2020 Jun 16. Epub 2020 Jun 16.

Sussex Health Outcomes Research & Education in Cancer (SHORE-C), University of Sussex, Sussex, UK.

Pulmonary metastasectomy is widely and increasingly practiced in the belief that this intervention can cure patients with colorectal cancer, and that without it few survive 5 years. No good evidence exists supporting such convictions, indeed recent trial results challenge them. What evidence underpins this acceptance of illusory truths or misconceptions? Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0927-2DOI Listing

Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.

Br J Cancer 2020 Jun 15. Epub 2020 Jun 15.

Children's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.

Background: While current chemotherapy has increased cure rates for children with acute lymphoblastic leukaemia (ALL), the largest number of relapsing patients are still stratified as medium risk (MR) at diagnosis (50-60%). This highlights an opportunity to develop improved relapse-prediction models for MR patients. We hypothesised that bone marrow from MR patients who eventually relapsed would regrow faster in a patient-derived xenograft (PDX) model after induction chemotherapy than samples from patients in long-term remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0933-4DOI Listing

Ibuprofen mediates histone modification to diminish cancer cell stemness properties via a COX2-dependent manner.

Br J Cancer 2020 Jun 12. Epub 2020 Jun 12.

Institute of Breast Research, Jining Medical University, Jining, 272067, China.

Background: The anticancer potential of ibuprofen has created a broad interest to explore the clinical benefits of ibuprofen in cancer therapy. However, the current understanding of the molecular mechanisms involved in the anticancer potential of ibuprofen remains limited.

Methods: Cancer stemness assays to validate ibuprofen function in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0906-7DOI Listing

Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis.

Br J Cancer 2020 Jun 12. Epub 2020 Jun 12.

School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.

Background: Mammography is not effective in detecting breast cancer in dense breasts.

Methods: A search in Medline, Cochrane, EMBASE and Google Scholar databases was conducted from January 1, 1980 to April 10, 2019 to identify women with dense breasts screened by mammography (M) and/or ultrasound (US). Meta-analysis was performed using the random-effect model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0928-1DOI Listing

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.

Br J Cancer 2020 Jun 11. Epub 2020 Jun 11.

King's College London and Guy's and St Thomas' NHS Foundation Trust, London, UK.

Background: This phase 1 study examined the safety, maximum-tolerated dose (MTD) and antitumour activity of E7449, a novel PARP 1/2 and tankyrase 1/2 inhibitor.

Methods: E7449 was orally administered once daily in 28-day cycles to patients with advanced solid tumours (50-800-mg doses). Archival tumour samples from consenting patients were evaluated for the expression of 414 genes in a biomarker panel (2X-121 drug-response predictor [DRP]) found to be predictive of the response to E7449 in cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0916-5DOI Listing

CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.

Br J Cancer 2020 Jun 8. Epub 2020 Jun 8.

Department of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region of China.

Background: CD109 was involved in the tumorigenesis and progression of various cancers via TGF-β1 signalling and STAT3 activation. As CD109 is strongly expressed in cervical squamous cell carcinoma, this study was conducted to investigate its functional characteristics in cervical cancer.

Methods: CD109 expression was examined by immunohistochemistry (IHC) with cervical tissue microarray. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0922-7DOI Listing

Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC).

Br J Cancer 2020 Jun 8. Epub 2020 Jun 8.

Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

This paper summarises the position of ESGO and EFC on cervical screening based on existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as this offers greater protection against cervical cancer and allows longer screening intervals. Only a dozen of HPV tests are considered as clinically validated for screening. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0920-9DOI Listing

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.

Br J Cancer 2020 Jun 8. Epub 2020 Jun 8.

Département de Gastroentérologie et d'Oncologie Digestive, Hôpital Européen George Pompidou, Paris, France.

Background: Chemo-embolisation with drug-eluting beads loaded with irinotecan (DEBIRI) increased survival as compared with intravenous irinotecan in chemorefractory patients with liver-dominant metastases from colorectal cancer (LMCRC). First-line DEBIRI with systemic chemotherapy may increase survival and secondary resection.

Methods: In the FFCD-1201 single-arm Phase 2 study, patients with untreated, non-resectable LMCRC received DEBIRI plus mFOLFOX6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0917-4DOI Listing

Oestrogen receptor pathway activity is associated with outcome in endometrial cancer.

Br J Cancer 2020 Jun 8. Epub 2020 Jun 8.

Department of Obstetrics and Gynaecology, Radboud Institute for Health Science, Radboud university medical center, Nijmegen, the Netherlands.

Background: Oestrogen receptor (ER) expression is a prognostic biomarker in endometrial cancer (EC). However, expression does not provide information about the functional activity of the ER pathway. We evaluated a model to quantify ER pathway activity in EC, and determined the prognostic relevance of ER pathway activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0925-4DOI Listing

ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.

Br J Cancer 2020 Jun 5. Epub 2020 Jun 5.

The Hormel Institute, University of Minnesota, Austin, MN, USA.

Background: Small cell lung cancer (SCLC) is the most aggressive form of lung cancer, and new molecular insights are necessary for prognostic and therapeutic advances.

Methods: Dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32) and its N-terminally truncated splice variant, t-DARPP, were stably overexpressed or ablated in human DMS-53 and H1048 SCLC cells. Functional assays and immunoblotting were used to assess how DARPP-32 isoforms regulate SCLC cell growth, proliferation, and apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0923-6DOI Listing
June 2020
4.836 Impact Factor

BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene.

Br J Cancer 2020 Jun 5. Epub 2020 Jun 5.

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Background: Oral squamous cell carcinoma (OSCC) has increased morbidity, and its high metastatic potential affects patient survival. Bromodomain containing 4 (BRD4) is a chromatin protein that associates with acetylated histone lysines and facilitates transcription. BRD4 has been implicated in cell proliferation, metastasis, and prognosis in several types of cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0907-6DOI Listing

Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity.

Br J Cancer 2020 Jun 5. Epub 2020 Jun 5.

Laboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.

Background: Host-microbiota interactions shape T-cell differentiation and promote tumour immunity. Although IL-9-producing T cells have been described as potent antitumour effectors, their role in microbiota-mediated tumour control remains unclear.

Methods: We analysed the impact of the intestinal microbiota on the differentiation of colonic lamina propria IL-9-producing T cells in germ-free and dysbiotic mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0915-6DOI Listing

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.

Br J Cancer 2020 Jun 4. Epub 2020 Jun 4.

Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.

Background: Expression of proton-coupled folate transporter (PCFT) is associated with survival of mesothelioma patients treated with pemetrexed, and is reduced by hypoxia, prompting studies to elucidate their correlation.

Methods: Modulation of glycolytic gene expression was evaluated by PCR arrays in tumour cells and primary cultures growing under hypoxia, in spheroids and after PCFT silencing. Inhibitors of lactate dehydrogenase (LDH-A) were tested in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0912-9DOI Listing

Resistance training and total and site-specific cancer risk: a prospective cohort study of 33,787 US men.

Br J Cancer 2020 Jun 4. Epub 2020 Jun 4.

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Background: Muscle-strengthening activities have been recommended for health benefits. However, it is unclear whether resistance training is associated with cancer risk, independent of total physical activity.

Methods: A prospective cohort study followed 33,787 men from the Health Professionals Follow-up Study (1992-2014). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0921-8DOI Listing

The relationships between systemic cytokine profiles and inflammatory markers in colorectal cancer and the prognostic significance of these parameters.

Br J Cancer 2020 Jun 3. Epub 2020 Jun 3.

Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea.

Background: Immunomodulatory cytokines and systemic inflammatory markers are important during cancer development and progression. This study investigated the association and prognostic impact of systemic cytokine profiles and inflammatory markers in colorectal cancer (CRC).

Methods: Interleukin (IL)-1β, IL-6, IL-8, IL-9, IL-10, tumour necrosis factor (TNF)-α and vascular endothelial growth factor (VEGF) serum levels were measured using multiplex bead assays in CRC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0924-5DOI Listing

Human Schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription.

Br J Cancer 2020 Jun 3. Epub 2020 Jun 3.

Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China.

Background: Human Schlafen 5 (SLFN5) has been reported to inhibit or promote cell invasion in tumours depending on their origin. However, its role in breast cancer (BRCA) is undetermined.

Methods: Differential expression analyses using The Cancer Genome Atlas (TCGA) data, clinical samples and cell lines were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0873-zDOI Listing

Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial.

Br J Cancer 2020 Jun 3. Epub 2020 Jun 3.

Aristotle University of Thessaloniki, Thessaloniki, Greece.

Background: Cabazitaxel is a novel taxane that might be active in breast cancer resistant to first-generation taxanes.

Methods: The purpose of the current multicentre phase II trial was to evaluate the activity and safety of cabazitaxel, as second-line treatment, in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) previously treated with taxanes. The primary endpoint was objective response rate (ORR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0909-4DOI Listing